Navigation Links
For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
Date:4/30/2013

BURLINGTON, Mass., April 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European infectious disease specialists agree that effect on recurrence rate is one of the drug attributes that most influences their prescribing decisions when treating Clostridium difficile infections (CDIs). Similarly, surveyed hospital pharmacy directors indicate a high willingness to grant favorable formulary status to therapies that can demonstrate a decrease in recurrence rates of CDIs. However, even though clinical data and interviewed key opinion leaders indicate that emerging therapies provide a significant advantage over current standard-of-care therapies, marketers will need to be cognizant of price in a CDI market dominated by inexpensive and efficacious alternatives.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Market Opportunity Awaits Therapies That Provide Low Rates of CDI Recurrences finds that surveyed U.S. infectious disease specialists would prescribe Cubist's surotomycin to 15 percent of their CDI patients, driven mostly by surotomycin's lower rate of CDI recurrence relative to oral vancomycin (ViroPharma's Vancocin; generics). However, Decision Resources forecasts that surotomycin will earn a more-modest patient share of 5 percent, constrained partially by continued uptake of fidaxomicin (Optimer/Cubist's Dificid; Astellas' Dificlir), which has already demonstrated superiority in recurrence rates over oral vancomycin.

"Uptake of surotomycin will likely be constrained, unless it can demonstrate either higher clinical efficacy than Dificid or offer more favorable pricing", said Decision Resources Analyst Maria Ascano Ph.D. "Other factors that will also limit surotomycin's uptake are competition from other emerging therapies like cadazolid (Actelion) and MK-3415A (Merck), generic entry of oral vancomycin capsules, and the continued use of oral preparations of IV vancomycin."

Nevertheless, surveyed hospital pharmacy directors are highly willing to grant favorable formulary inclusion to therapies that provide increased clinical cure rates, particularly in CDI patients that suffer from severe and/or recurrent infections. As a result, market opportunity awaits therapies that can demonstrate higher overall clinical efficacy in patients with difficult-to-treat CDIs.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
3. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
4. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
5. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
6. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
7. The Growing Cost of Aging: Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
8. The Nairobi Hospital in Kenya Commences Treating Cancer with Advanced Radiotherapy Delivery Using Varian Equipment and Software
9. Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
10. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
11. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):